Erythropoietin

Krantz, Sanford B.; Gräber, Stanley E.

doi:10.1016/b978-0-12-595705-2.50022-7

Cited by 202 publications

(255 citation statements)

References 209 publications

Supporting

Mentioning

247

Contrasting

Unclassified

Order By: Relevance

“…There are two possibilities: A) HGF enhances the expression of EPO-R on the CD34 + progenitor cells, since it has been reported that EPO-R expression on the cell membrane of progenitor cells is critical during the erythroid differentiation process [33], and B) HGF augments the signal transduction from EPO-R. In the present study, we have shown that the EPO/EPO-R-mediated signals are enhanced markedly, and Stat 5 plays an essential role in the effect of HGF action on early erythropoiesis, whereas the expression level of EPO-R remains unchanged.…”

Section: Discussionmentioning

confidence: 99%

HGF Activates Signal Transduction from EPO Receptor on Human Cord Blood CD34 ⁺ /CD45 ⁺ Cells

et al. 1999

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

HGF Activates Signal Transduction from EPO Receptor on Human Cord Blood CD34 ⁺ /CD45 ⁺ Cells

et al. 1999

View full text Add to dashboard Cite

show abstract

“…is a glycoprotein hormone produced in the fetal liver and adult kidney, which plays a major role in increasing production of red blood cells in response to anemia or hypoxia (Krantz, 1991). Expression of EPO and EPO receptor mRNA is present in the neural retina as early as 8 weeks gestation, although its role remains unclear (Juul et al, 1998).…”

Section: Erythropoietin (Epo)-epomentioning

confidence: 99%

Vascular endothelial growth factor in eye disease

Penn

Madan

Caldwell

et al. 2008

Progress in Retinal and Eye Research

615

527

View full text Add to dashboard Cite

Collectively, angiogenic ocular conditions represent the leading cause of irreversible vision loss in developed countries. In the U.S., for example, retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration are the principal causes of blindness in the infant, working age and elderly populations, respectively. Evidence suggests that vascular endothelial growth factor (VEGF), a 40 kDa dimeric glycoprotein, promotes angiogenesis in each of these conditions, making it a highly significant therapeutic target. However, VEGF is pleiotropic, affecting a broad spectrum of endothelial, neuronal and glial behaviors, and confounding the validity of anti-VEGF strategies, particularly under chronic disease conditions. In fact, among other functions VEGF can influence cell proliferation, cell migration, proteolysis, cell survival and vessel permeability in a wide variety of biological contexts. This article will describe the roles played by VEGF in the pathogenesis of retinopathy of prematurity, diabetic retinopathy and age-related macular degeneration. The potential disadvantages of inhibiting VEGF will be discussed, as will the rationales for targeting other VEGF-related modulators of angiogenesis.

show abstract

“…1 The primary sites of physiologic, hypoxia-inducible erythropoietin production include the fetal liver and adult kidney. 2 The ability of the recombinant form of human erythropoietin to stimulate the production of red blood cells has led to its widespread clinical use in patients with various chronic diseases that are associated with anemia, such as cancer.…”

mentioning

confidence: 99%

Erythropoietin and erythropoietin receptor expression in human prostate cancer

et al. 2005

View full text Add to dashboard Cite

Erythropoietin is a hematopoietic cytokine that regulates the production of red blood cells. Erythropoietin is normally produced in the adult kidney in a hypoxia-inducible manner. The recombinant form of human erythropoietin is in clinical use for the prevention and treatment of anemia that is associated with cancer and its treatment with chemoradiation therapy. A series of recent studies from our laboratory and others have reported the expression of receptors for erythropoietin in several different types of human cancer cells. In the present study, we investigated the expression of erythropoietin receptor and its ligand erythropoietin in human prostate cancer. In clinical specimens of prostate cancer, we found abundant expression of erythropoietin receptor protein in all primary tumors examined using immunohistochemistry. Furthermore, we observed erythropoietin coexpression in prostate cancer cells by immunohistochemical analysis. To determine whether monolayer cultures of continuous cell lines derived from prostate cancer also express erythropoietin receptor and erythropoietin, we studied well-characterized hormone-responsive (LNCaP) and hormone-refractory (PC-3) prostate cancer cell lines. We performed reverse-transcription and polymerase chain reaction assays to detect erythropoietin receptor and erythropoietin mRNA transcripts, and also immunoprecipitation and immunoblotting to detect erythropoietin receptor protein expression in prostate cancer cells. These experiments revealed the expression of both erythropoietin receptor and erythropoietin in LNCaP and PC-3 cells suggesting that these prostate cancer cell lines may serve as useful experimental models for further studies of erythropoietin and erythropoietin receptor function in prostate cancer. The coexpression of erythropoietin receptor and its ligand erythropoietin in human prostate cancer cells suggests the potential for growth regulation by erythropoietin-erythropoietin receptor in an autocrine or paracrine manner.

show abstract

Erythropoietin

Cited by 202 publications

References 209 publications

HGF Activates Signal Transduction from EPO Receptor on Human Cord Blood CD34 ⁺ /CD45 ⁺ Cells

HGF Activates Signal Transduction from EPO Receptor on Human Cord Blood CD34 ⁺ /CD45 ⁺ Cells

Vascular endothelial growth factor in eye disease

Erythropoietin and erythropoietin receptor expression in human prostate cancer

Contact Info

Product

Resources

About

Erythropoietin

Cited by 202 publications

References 209 publications

HGF Activates Signal Transduction from EPO Receptor on Human Cord Blood CD34 + /CD45 + Cells

HGF Activates Signal Transduction from EPO Receptor on Human Cord Blood CD34 + /CD45 + Cells

Vascular endothelial growth factor in eye disease

Erythropoietin and erythropoietin receptor expression in human prostate cancer

Contact Info

Product

Resources

About

HGF Activates Signal Transduction from EPO Receptor on Human Cord Blood CD34 ⁺ /CD45 ⁺ Cells

HGF Activates Signal Transduction from EPO Receptor on Human Cord Blood CD34 ⁺ /CD45 ⁺ Cells